Design Therapeutics (DSGN) Current Assets (2020 - 2026)

Design Therapeutics has disclosed Current Assets across 7 years of filings, most recently posting $227.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $227.0 million, down 2.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $227.0 million (down 2.82% YoY), and the FY2025 annual result was $223.8 million, down 9.78% from the prior year.
• Current Assets came in at $227.0 million for Q1 2026 at Design Therapeutics, up from $223.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $373.9 million in Q1 2022 to a low of $209.0 million in Q3 2025.
• The 5-year median for Current Assets is $273.9 million (2024), against an average of $281.2 million.
• Across the five-year window, Current Assets decreased 18.74% in 2025 and fell 2.82% in 2026, its largest moves.
• Design Therapeutics' Current Assets stood at $335.1 million in 2022, then dropped by 15.08% to $284.6 million in 2023, then declined by 12.84% to $248.0 million in 2024, then decreased by 9.78% to $223.8 million in 2025, then rose by 1.46% to $227.0 million in 2026.
• The last three Current Assets figures came in at $227.0 million (Q1 2026), $223.8 million (Q4 2025), and $209.0 million (Q3 2025), per Business Quant data.